About Us
BirchBioMed is a cutting-edge clinical-stage biopharmaceutical company headquartered in Canada. The company is dedicated to pioneering innovative treatments for organ fibrosis, scarring (fibrosis) and associated skin disorders, as well as specific subsets of autoimmune disorders, including Type 1 Diabetes and Alopecia Areata.
Our Mission
At BirchBioMed, we are committed to transforming lives through the development of groundbreaking therapies for organ fibrosis, specific autoimmune disorders, and severe skin disorders. With a focus on innovative treatments like FS2 and AI-001, we strive to deliver curative solutions that offer new hope to millions of patients worldwide.
Leadership
BirchBioMed’s senior leadership team and board of directors consist of industry veterans with decades of experience in the biopharmaceutical sector. With a deep passion for scientific innovation, they are dedicated to advancing cutting-edge therapies that address fibrosis, autoimmune diseases, and severe skin disorders.
Grants
Our technology has received more than six million dollars in grants and in-kind funding from prestigious institutions, underscoring the strength and potential of our science. These awards reflect the confidence leading organizations have in our innovative approach to treating fibrosis, specific autoimmune disorders, and related conditions.
